Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 93

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 93
---
 multiplied by $10.00 and (ii) 25.0%). The deferred fee becomes payable to the
underwriters from the amounts held in the trust account solely in the event that we complete a business combination, subject to the terms
of the underwriting agreement. In addition, we agreed to issue the underwriters 200,000 ordinary shares (or up to 230,000 ordinary shares
if the over-allotment option is exercised in full), denoted as representative shares.

22

Critical
Accounting Estimates

The
preparation of unaudited financial statements and related disclosures in conformity with accounting principles generally accepted in
the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the unaudited financial statements, and income and expenses during the
periods reported. Actual results could materially differ from those estimates. We have not identified any critical accounting estimates.

Recent
Accounting Standards

In
November 2024, the FASB issued Accounting Standards Update (“ASU”) 2024-03, “Income Statement-Reporting Comprehensive
Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”, requiring public entities
to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual
basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December
15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. 

Management
does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material
effect on our unaudited financial statements.

Item
3. Quantitative and Qualitative Disclosures About Market Risk.

We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this item. Following the consummation of our Initial Public Offering, the net proceeds of our Initial Public Offering,
including amounts in the trust account, have been invested in U.S. government treasury obligations with a maturity of 185 days or less
or in certain money market funds that invest solely in U.S. treasuries. Due to the short-term nature of these investments, we believe